EC
COGT icon

EntryPoint Capital’s Cogent Biosciences COGT Stock Holding History

EntryPoint Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$428K Buy
+11,123
New +$411K 0.13% 314
2025
Q2 		– Sell
-28,005
Closed -$168K – 648
2025
Q1 		$168K Sell
28,005
-24,341
-47% -$191K 0.08% 572
2024
Q4 		$408K Buy
+52,346
New +$522K 0.17% 197
2024
Q2 		– Sell
-31,292
Closed -$210K – 1006
2024
Q1 		$210K Sell
31,292
-1,751
-5% -$10.8K 0.19% 100
2023
Q4 		$194K Buy
+33,043
New +$253K 0.19% 102

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

EntryPoint Capital's COGT Position: Q1 2026 in Review

EntryPoint Capital opened a new position in Cogent Biosciences (COGT) in Q1 2026: 11,123 shares worth $428K. The stake represents 0.13% of the portfolio and ranks #314 among its holdings. This is a return to the name: EntryPoint Capital previously reported a position in COGT as recently as Q1 2025.

EntryPoint Capital first reported a position in COGT in Q4 2023 and has held it in 5 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • EntryPoint Capital held 11,123 shares of Cogent Biosciences worth $428K as of Q1 2026.
  • Cogent Biosciences was a new EntryPoint Capital position in Q1 2026.
  • Cogent Biosciences made up 0.13% of EntryPoint Capital's portfolio in Q1 2026, its #314 holding.
  • EntryPoint Capital first reported a position in Cogent Biosciences in Q4 2023 and has held it in 5 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on EntryPoint Capital's 13F filing for Q1 2026, filed 14 May 2026.